Logo of genesdevCSHL PressJournal HomeSubscriptionseTOC AlertsBioSupplyNetGenes & Development
Genes Dev. 2002 Jul 1; 16(13): 1640–1658.
PMCID: PMC186374

Nercc1, a mammalian NIMA-family kinase, binds the Ran GTPase and regulates mitotic progression


The protein kinase NIMA is an indispensable pleiotropic regulator of mitotic progression in Aspergillus. Although several mammalian NIMA-like kinases (Neks) are known, none appears to have the broad importance for mitotic regulation attributed to NIMA. Nercc1 is a new NIMA-like kinase that regulates chromosome alignment and segregation in mitosis. Its NIMA-like catalytic domain is followed by a noncatalytic tail containing seven repeats homologous to those of the Ran GEF, RCC1, a Ser/Thr/Pro-rich segment, and a coiled-coil domain. Nercc1 binds to another NIMA-like kinase, Nek6, and also binds specifically to the Ran GTPase through both its catalytic and its RCC1-like domains, preferring RanGDP in vivo. Nercc1 exists as a homooligomer and can autoactivate in vitro by autophosphorylation. Nercc1 is a cytoplasmic protein that is activated during mitosis and is avidly phosphorylated by active p34Cdc2. Microinjection of anti-Nercc1 antibodies in prophase results in spindle abnormalities and/or chromosomal misalignment. In Ptk2 cells the outcome is prometaphase arrest or aberrant chromosome segregation and aneuploidy, whereas in CFPAC-1 cells prolonged arrest in prometaphase is the usual response. Nercc1 and its partner Nek6 represent a new signaling pathway that regulates mitotic progression.

Keywords: NIMA, NEK, Ran, RCC1, cdc2/MPF, mitosis

Cell division is timed and controlled in part through the interplay of a specialized set of protein kinases and phosphatases, the best known of which are the cyclin-dependent kinases (CDK). Recent studies indicate, however, that several other families of protein kinases also play important roles at different stages of this intricate process (Nigg 2001). Polo-like kinases (Glover et al. 1998), Aurora kinases (Bischoff and Plowman 1999), and NIMA-like kinases (Neks) (Fry and Nigg 1997; Kandli et al. 2000) have been implicated in such processes as centrosome separation and chromosome condensation in prophase, nuclear envelope breakdown and spindle assembly in prometaphase, as well as in exit from mitosis and cytokinesis.

Neks are named for the Aspergillus nidulans protein kinase encoded by the nimA gene (Osmani and Ye 1996). Early data suggested that NIMA cooperates with p34Cdc2/cyclin B during the onset of mitosis, perhaps by enabling nuclear entry of cyclin B/p34Cdc2 (Wu et al. 1998). Moreover, both Cdc2 and NIMA must be inactivated for mitotic exit. Temperature-sensitive mutations of the nimA gene (Osmani et al. 1991a) or expression of the noncatalytic domain of NIMA (Lu and Means 1994) arrest Aspergillus cells in G2 (thus the name NIM, never in mitosis) without interfering with p34Cdc2 activation. Conversely, overexpression of NIMA causes chromatin condensation and abnormal spindle formation without activating p34Cdc2 (Osmani et al. 1988a; O'Connell et al. 1994). G2 arrest of nimA mutants can be bypassed by mutation of different anaphase-promoting complex (APC) subunits. Double nimA + APC mutants can enter mitosis when shifted to restrictive temperature, although mitotic cells show aberrant nuclear envelopes and spindle organization, pointing to an involvement of the NIMA protein kinase in mitotic processes beyond the control of the G2/M transition (Osmani et al. 1988b, 1991b; Lies et al. 1998).

NIMA protein levels are maximal during mitosis, and NIMA protein kinase activity seems to parallel NIMA protein content (Osmani et al. 1991b; Ye et al. 1995). NIMA is hyperphosphorylated in vivo during mitosis and can be phosphorylated in vitro by p34Cdc2 (Ye et al. 1995). Such in vitro phosphorylation alters NIMA protein kinase activity modestly; however, once phosphorylated in mitosis, NIMA is rapidly degraded, and this degradation is necessary for mitotic exit (O'Connell et al. 1992; Pu and Osmani 1995).

The ability of recombinant NIMA to induce chromatin condensation in fission yeast (O'Connell et al. 1994) and vertebrate cells (accompanied in the latter by nuclear membrane breakdown; O'Connell et al. 1994; Lu and Hunter 1995) as in Aspergillus, suggests that a protein kinase with similar specificity participates in cell cycle control in higher metazoans. At least eight mammalian NIMA-related kinases, or Neks (Nigg 2001), have been identified; however, none has emerged as a bona fide functional homolog of NIMA, that is, as necessary for mitotic progression, or able to induce chromatin condensation if overexpressed. The Neks are most closely related to NIMA in their catalytic domain sequences, but each diverges substantially from NIMA in its noncatalytic C-terminal tail, including the Neurospora crassa NIMA-related kinase that has the capacity to complement the nimA mutation (Pu et al. 1995). Nek2, the mammalian homolog most similar in overall amino acid sequence to NIMA, is involved in the regulation of centrosomal structure and function (Mayor et al. 1999), but does not appear to be involved in other aspects of mitosis. The functions of other Neks are largely unknown, although recently Nek6, and the closely related Nek7, recent mammalian additions to the family (Kandli et al. 2000), were shown to phosphorylate the protein kinase p70 S6 kinase on Thr412 within a hydrophobic motif, a phosphorylation that, together with the PDK1-catalyzed phosphorylation of Thr252 in the activation loop, mediates activation of the p70 S6 kinase (Belham et al. 2001).

Herein we describe a new member of the NIMA-like family of protein kinases, which we designate Nercc1 kinase. This enzyme was identified by its tight binding to overexpressed recombinant Nek6. Nercc1 kinase is activated during mitosis, binds specifically to the Ran GTPase, and is a substrate for Cdc2 phosphorylation. Overexpression of both active and inactive variants of the Nercc1 kinase is toxic to cells, inhibiting cell division and causing abnormal nuclear morphologies. Microinjection of anti-Nercc1 antibodies in prophase, that is, after chromosome condensation, interferes with spindle organization and correct segregation of the chromosomes, resulting in either prometaphase arrest or aneuploidy. Nercc1 kinase appears to play one or more central roles in the control of mitotic progression, possibly regulated by p34Cdc2 and the Ran GTPase.


Cloning of Nercc1, a novel protein kinase in the NIMA family

Immunoaffinity purification of a Flag–Nek6 polypeptide overexpressed in HEK293 cells results in the recovery of an associated 120-kD polypeptide. Incubation of the Flag–Nek6 immunoprecipitate with Mg2+ plus [γ-32P]ATP yields 32P incorporation into both Nek6 and p120 to a similar extent, suggesting that p120 is a substrate for Nek6, a protein kinase itself, or both (Fig. (Fig.1a).1a). Tryptic digests of the 120-kD band were analyzed by electrospray ionization mass spectrometry. Spectra corresponding to multiple peptide sequences were identified on each of three successive ORFs predicted by GENESCAN (Burge and Karlin 1997) on the human BAC clone 201F1 (AC007055). The sum of the molecular masses of the three polypeptides predicted by these ORFs was close to 120 kD, suggesting that the exon–intron boundaries had been determined incorrectly by GENESCAN. Further analysis, using GENEMARK (Borodovsky and McIninch 1993) or GENESCAN, yielded predictions containing all three original ORFs (AAD31938, AAD31939, and AAD31940) in polypeptides of ∼100 kD (107 kD and 91 kD, respectively).

Figure 1
Nek 6 coimmunoprecipitates with a 120-kD protein. Structure of Nercc1 polypeptide. (a) HEK293 cells were transfected with either empty vector (−) or pCM5 Flag–Nek6 (+). Cell lysates were prepared 48 h later, and Nek6 was immunoprecipitated ...

Using the predicted sequences and supporting ESTs, a cDNA containing the complete coding region for a protein of 979 residues containing all the peptides identified by MS was cloned by PCR (see Supplementary Fig. 1a; the nucleotide sequence along with a translation of the coding region is shown in Supplementary Fig. 1b; Supplemental Material available online at http://www.genesdev.org). The predicted protein product (Fig. (Fig.1b)1b) has a calculated molecular mass of 107,034 D, a theoretical pI of 5.50, and contains all 29 peptides detected in the tryptic digest of the 120-kD protein band. The polypeptide has a typical eukaryotic protein kinase domain situated near the N terminus (residues 52–308) that shows all the features of a functional serine/threonine protein kinase. The catalytic domain is most similar to the NIMA-related family of protein kinases (39%–44% identity and 56%–66% similarity with vertebrate Neks, 33% identity and 49% similarity with NIMA). Immediately following the catalytic domain is a nuclear localization signal (NLS) composed of two classical nuclear localization motifs (306PLLRKRRR313 and 325PTKRPR330). Thereafter is a domain containing seven consecutive RCC1 (regulator of chromosome condensation) repeats (residues 347–726; Fig. Fig.1c),1c), followed by a segment containing nine consecutive glycine residues (752–760), encompassed within a PEST region (734–779); the polyglycine segment is likely to act as a flexible hinge. An acidic serine/threonine/proline-rich segment (761–890) follows next, which includes two motifs that conform to the SH3-domain-binding sequence PXXP (823PXPXXPXP830 and 881KXXPXXPP888), and seven SP and TP sites (four overlapping the PXXP motifs). Immediately succeeding this region is a predicted coiled-coil domain (891–940), followed by the protein C terminus. We designate this polypeptide as Nercc1 kinase, based on the similarity of the kinase domain to the NIMA/Nek kinases, and the presence of an RCC1-like domain.

Although there is no significant identity in the primary sequences of the C-terminal noncatalytic segments of NIMA and the Nercc1 kinase, these two segments do share several related features, namely, a nuclear localization signal immediately following the catalytic domain, a proline-rich segment containing multiple SP and TP sites (some of which, in the case of NIMA, are probably phosphorylated during mitosis and appear to be important for regulation; Fry and Nigg 1995; Osmani and Ye 1996), and a coiled-coil domain. In addition, several PEST regions (involved in control of protein stability) are found in both protein kinases.

A striking difference between Nercc1 protein kinase, NIMA, and the Neks characterized thus far in higher eukaryotes is the presence in the Nercc1 kinase of a domain homologous to the RCC1 protein. RCC1 is a guanine-nucleotide-exchange factor for the small G-protein Ran, and is composed of seven repeats of 51–68 residues folded in a structure that resembles a seven-blade propeller (Renault et al. 1998). The Nercc1 RCC1 domain has a 27% identity and 43% similarity to RCC1, and like RCC1 contains seven tandem repeats (Fig. (Fig.1c).1c). We have been unable to detect a protein kinase with this domain organization in lower eukaryotes; interestingly, a hypothetical protein kinase in the genome of Drosophila melanogaster (accession code AAF56344) shows an architecture homologous to Nercc1 kinase, that is, an N-terminal NIMA-related protein kinase domain followed by a series of RCC1 domain repeats.

During the revision of this paper, the sequences of two different mammalian NIMA-family kinases containing an RCC1 domain appeared in GenBank. One, cloned from mouse (accession code AF407579) and zebrafish (AF407580) by Beier and colleagues (S. Liu, W. Lu, T. Obara-Ishibara, I. Drummond, and D.R. Beier. A defect in a novel Nek-family kinase causes cystic disease in the mouse and in zebrafish. unpubl.), has been named Nek8. Mouse Nek 8 is a protein of 698 residues, 32% identical and 49% similar to the first 752 residues of Nercc1. It lacks the C-terminal tail that in Nercc1 spans from the polyglycine region to the end of the protein; this is an important regulatory region in Nercc1 (see below). A second protein kinase identical in sequence to Nercc1 has been deposited in GenBank; this can be accessed both as Nek8 (AY048580) and Nek9 (NM033116) (Holland et al. 2002).

The Nercc1 protein kinase is expressed in all human cell lines tested, including HEK293, HeLa, and U2OS cells; Nercc1 protein expression is detected in these and other mammalian cell lines, as well as in all mouse tissues tested (see Supplemental Fig. 2).

Nercc1 interaction with Nek6

We sought to confirm the association of Nek6 with recombinant Nercc1 by coexpression of GST–Nek6 and Flag–Nercc1 in 293 cells. Full-length Flag–Nercc1 is seen to bind specifically to GST–Nek6, whereas the C-terminally truncated Flag–Nercc1(1–739), despite comparable expression, is unable to bind GST–Nek6 (Fig. (Fig.2a).2a). Reciprocally, the fusion of the Nercc1 kinase C-terminal segment, Nercc1(732–979), to GST is sufficient to enable specific binding of Flag–Nek6 (Fig. (Fig.2b).2b). Further analysis (see below) indicates that the site of Nek6/Nercc1 interaction lies between the Nercc1 amino acids 732 and 891.

Figure 2
Nercc1 binding to Nek6. (a) HEK293 cells were cotransfected with full-length (FL) Flag–Nercc1 or Flag–Nercc1(1–739), and either GST–Nek6 or GST alone. GST fusion proteins were isolated from cell lysates using GSH-agarose ...

Nercc1 homodimerizes through a coiled-coil domain distinct from the Nek6-binding site

Nercc1 contains a predicted coiled-coil motif near its C terminus (residues 891–940), a likely candidate for an oligomerization domain (Fig. (Fig.3a).3a). The ability of Nercc1 to form homooligomers is shown by the coprecipitation of Flag–Nercc1 with HA–Nercc1 (Fig. (Fig.3b).3b). The Nercc1(891–940) segment was fused to GST and coexpressed with either full-length Flag–Nercc1 or Flag–Nercc1 deleted of its C-terminal 89 residues (Nercc1 residues 1–891). Figure Figure3c3c shows that although full-length Nercc1 associates specifically with GST–Nercc1(891–940), deletion of the C-terminal 89 residues of Nercc1 abolishes this association (Fig. (Fig.3c,3c, left panel). In addition, Nercc1(1–891) cannot oligomerize with full-length Nercc1 (Fig. (Fig.3c,3c, right panel). Thus, Nercc1 oligomerizes through its C-terminal coiled-coil domain. As shown below, this oligomerization is important for the regulation of Nercc1 protein kinase activity.

Figure 3
Nercc1 oligomerizes through its C-terminal coiled-coil domain. (a) Nercc1 coiled-coil prediction carried out with the Coils 2.1. software (window 28). The propensity of a sequence to form coiled coils on a scale from 0 to 1 is plotted against the linear ...

Gel filtration analysis of both recombinant and endogenous Nercc1 in 293 cells shows that the protein kinase exists in a high molecular mass complex of ∼600 kD (Fig. (Fig.3d).3d). The larger-than-expected size probably reflects the association of Nercc1 with other proteins such as Nek6, and perhaps higher-order homooligomers and/or a complex of asymmetric shape.

The 891–940 deletion does not affect Nek6 interaction with Nercc1; full-length Nercc1 and Nercc1(1–891) both interact with Nek6 with similar affinities. Moreover, GST–Nercc1(891–940) does not bind Nek6 (data not shown). Thus, Nek6 binds to Nercc1 between amino acids 732 and 891, that is, in the region between the end of the Nercc1 RCC1 domain and the beginning of the coiled-coil domain.

Protein kinase activity of Nercc1

The catalytic properties of Nercc1 were studied using immunoprecipitates of Flag-tagged forms of the Nercc1 polypeptide transiently expressed in HEK293 cells. The specificity of the measured protein kinase activity for the Nercc1 polypeptide was verified by the inability of an ATP-binding site mutant of Nercc1 (K81M) to catalyze significant 32P transfer to itself or exogenous substrates (Fig. (Fig.4b,4b, lanes 3,4). Thus, the kinase activity described below is caused by Nercc1 and not a contaminating protein kinase (e.g., Nek6). Nercc1 can autophosphorylate and phosphorylate different histones and MBP, whereas β-casein is phosphorylated much less rapidly (data not shown). Phosphoamino acid analysis of Nercc1 autophosphorylation and phosphorylation of histone H3 showed that Nercc1 phosphorylates serine and threonine residues exclusively (data not shown). Recombinant wild-type Nercc1 has low basal activity when extracted from exponentially growing cells; however, preincubation with Mg2+ plus ATP (100 μM) induces Nercc1 autophosphorylation (accompanied by a slowing in electrophoretic mobility) and activation (this activation can be reversed by phosphatase treatment; see below). The rate of in vitro activation is greatly enhanced if Mn2+ replaces Mg2+ (data not shown). Autophosphorylation/autoactivation is time and ATP concentration dependent; importantly, 10 μM ATP fails to enable significant Nercc1 activation even after incubation times of 90 min at 25°C, whereas 100 μM ATP gives maximal activation (10- to 20-fold) by 60 min, with half-maximal activation at 20 min (Fig. (Fig.4a).4a). Once activation is complete, Nercc1 catalyzes a robust phosphorylation of H3 at 5 μM to 10 μM ATP. This apparent increase in affinity for ATP after activation enables the design of a Nercc1 kinase assay that reflects the extent of activation achieved. Notably, endogenous Nercc1, immunoprecipitated out of exponentially growing cells by specific antibodies, shows a similar pattern of Mg2+ ATP-dependent autoactivation in vitro. Nercc1 is able to use GTP as a phosphate donor; GTP supports autoactivation, and after maximal autoactivation in vitro, enables the phosphorylation of histone H3 at ∼30% the rate observed with ATP (data not shown).

Figure 4
Nercc1 autoactivation in vitro. (a) Flag–Nercc1 was immunoprecipitated from HEK293 cells, washed, and incubated at 25°C in phosphorylation buffer for the indicated times with 10 μM or 100 μM ATP. Incubations were terminated ...

We next carried out a structure–function analysis of the ability of recombinant Nercc1 kinase to autoactivate in vitro. A series of Nercc1 variants, transiently expressed in HEK293 cells, was assayed for H3 kinase activity after preincubation at 25°C for 30 min with Mg2+ alone or Mg2+ plus 100 μM ATP, the latter a condition sufficient to enable near-maximal autoactivation of wild-type Nercc1 (Fig. (Fig.4a).4a). After washing away the nonradioactive ATP, the H3 kinase assay was commenced using a concentration of [γ-32P]ATP (5 μM to 10 μM) below that capable of supporting autoactivation of wild-type Nercc1 kinase (Fig. (Fig.4b,4b, lanes 1,2). An ATP-binding loop mutant of Nercc1 (K81M) shows no significant autophosphorylation/kinase activity irrespective of preincubation with Mg2+ ATP (Fig. (Fig.4b,4b, lanes 3,4); this is also true of Nercc1(338–979), which lacks entirely the Nercc1 protein kinase domain (data not shown). Nercc1(1–391), which lacks the RCC1 domain and the C-terminal tail, shows a low basal protein kinase activity but can be modestly activated by preincubation with Mg2+ and 100 μM ATP (Fig. (Fig.4b,4b, lanes 5,6, and 4c); Nercc1(1–391, K81M) is entirely devoid of activity (Fig. (Fig.4b,4b, lanes 7,8), as is Nercc1(1–308), which terminates the end of the canonical kinase domain (data not shown). Nercc1(1–739) retains both the protein kinase domain and the RCC1 domain, but is nevertheless inactive and incapable of autoactivation (Fig. (Fig.4b,4b, lanes 9,10). Deletion of the coiled-coil domain Nercc1(1–889) greatly diminishes the rate of autoactivation (Fig. (Fig.4b,4b, lanes 11,12), whereas deleting the proline-rich C-terminal segment but retaining the coiled coil (Δ763–889) permits substantial autoactivation (Fig. (Fig.4b,4b, lanes 13,14). Selective deletion of the RCC1 domain, Nercc1(Δ347–732), results in a very high basal H3 kinase activity as compared with wild-type Nercc1, which is not further increased by preincubation in vitro with Mg2+ plus 100 μM ATP (Fig. (Fig.4b,4b, lanes 15,16, and 4c). A more detailed examination of the time course of activation by ATP (100 μM) shows that although both Nercc1(1–391) and Nercc1(1–889) are capable of autoactivation, the rate is greatly diminished as compared with wild type. Thus deletion of the RCC1 domain produces a mutant with a basal activity similar to the maximal attainable by autoactivation (although the Δ347–732 polypeptide is less stable at 25°C); however, if the C-terminal dimerization domain is also deleted, as in Nercc1(1–391), the basal activity returns to low levels and autoactivation is severely retarded.

These results suggest a mechanism for Nercc1 kinase regulation (at least in vitro) in which the Nercc1 homodimer is maintained in an inhibited state by the ability of the RCC1 domain to abrogate intramolecular autophosphorylation. The inability of autoactivation to occur at ATP concentrations that enable robust phosphate transfer once activation has occurred suggests that the inhibitory action of the RCC1 domain operates, at least in part, by obstruction of the ATP-binding site. One prediction of this model is that the RCC1 domain and the kinase domain of Nercc1 are likely to interact. The occurrence of such an interaction is shown in Figure Figure4d;4d; Flag–Nercc1(338–739) expressed in HEK293 cells associates directly with coexpressed HA–Nercc1(1–391), supporting the view that the RCC1 domain may inhibit the kinase domain through a direct interaction. Nercc1 autophosphorylation is likely to occur in trans within the homodimer, as deletion of the RCC domain results in spontaneous activation in vivo only if the C-terminal tail, that is, the ability to homodimerize, remains intact.

Although this model fits the data for Nercc1 activation in vitro it is obvious that, inasmuch as the intracellular ATP concentration is 2 mM to 5 mM, the low basal activity of recombinant and endogenous Nercc1 kinase must reflect the operation in vivo of one or more negative regulatory inputs, in addition to the inhibition provided by the RCC1-like domain. Such inputs could include protein phosphatases, as well as inhibitory ligands or polypeptides.

Nercc1 binds to Ran

The presence in Nercc1 of a domain homologous to RCC1, a nucleotide exchange factor protein for the Ran GTPase, raises the question of whether Nercc1 binds Ran, and if so, to what functional effect. Prokaryotic recombinant GST and GST fusions with the Nercc1 kinase domain—GST–Nercc1(1–391), the RCC1 domain—GST–Nercc1(338–739), and the C-terminal tail—GST–Nercc1(732–979) were immobilized on GSH-agarose beads and incubated with prokaryotic recombinant Ran that had been preloaded with GTPβS or GTPγS. Whereas neither GST nor GST–Nercc1(732–979) bind Ran, the GST–Nercc1 kinase domain and RCC1-like domain fusion proteins are able to bind Ran with very high efficiency (Fig. (Fig.5a).5a). Both Nercc1 domains bind Ran-GDP to a somewhat greater extent than Ran-GTP; however, the degree of this preference is somewhat variable between experiments.

Figure 5
Nercc1 binding to Ran. (a) The binding of recombinant Ran to GST–Nercc1 variants in vitro. GST and GST–Nercc1 variants were purified and immobilized on GSH-agarose. Ran was produced in bacteria as a GST fusion, purified, cleaved from the ...

To examine the interaction between Ran and Nercc1 in vivo, we coexpressed HA–wild-type Ran (wild type) with different Flag–Nercc1 mutants, and probed the Flag immunoprecipitates for the presence of HA–wild-type Ran. Cell lysis and subsequent washes were carried out in the presence of excess Mg2+ to conserve Ran in its nucleotide-bound form. Figure Figure5b5b shows that wild-type Ran associates with full-length Nercc1 (both wild-type and K81M) as well as with the isolated Nercc1 catalytic domain fragments, 1–308 and 1–391, as expected from Figure Figure5a.5a. The specificity of this interaction was assessed by examining the relative ability of Ran to bind the Nercc1 catalytic domain, Nercc1(1–308), or Nek 6, another protein kinase in the NIMA subfamily (Fig. (Fig.5c);5c); no binding of HA–Ran to Nek6 is detectable, whereas both the Nercc1 catalytic domain and RCC1 (the Ran GEF, a positive control) bind avidly to Ran.

The deletion of the RCC1 domain, Nercc1(Δ347–732), or the C-terminal tail, Nercc1(1–739), does not detectably impair the binding of HA–Ran, and in contrast to the in vitro results, the isolated Nercc1 RCC1-like domain, Nercc1(338–739), shows very little association with Ran. The inability of the Nercc1 RCC1 domain to bind Ran in vivo is as yet unexplained. The RCC1-like domain may simply bind Ran with lower affinity than the catalytic domain; conversely, access of Ran to the isolated Nercc1 RCC1-like domain in vivo may be obstructed.

We next addressed the relative binding in vivo of Nercc1 to Ran-GDP versus Ran-GTP. A potential confounding element in assessing the interactions of Nercc1 with the different forms of Ran in vivo is the subcellular localization of the various partners; in interphase cells Ran-GDP is located exclusively in the cytoplasm, whereas Ran-GTP is restricted to the nucleus (Kalab et al. 2002), a situation maintained by the nuclear location of the Ran GEF, RCC1, and the cytosolic localization of Ran GAP. We therefore coexpressed either full-length, wild-type Nercc1, which is exclusively cytoplasmic (see below) or a nuclear-targeted form of full-length Nercc1 (NLS-Nercc1) with wild-type Ran or Ran mutants that bind GDP (T24N) or GTP (G19V) exclusively; either Ran or Nercc1 was immunoprecipitated and probed for the association with the other polypeptide. Figure Figure5d5d shows that full-length, wild-type Nercc1 binds coexpressed wild-type Ran and Ran T24N to a greater extent than RanG19V. Although this suggests a preference for Ran-GDP, it should be recalled that whereas RanT24N and Nercc1 are both cytoplasmic, RanG19V is exclusively nuclear in localization. However NLS-Nercc1, which is exclusively nuclear (see Fig. Fig.7c7c below), also does not bind the GTP-locked mutant RanG19V, strongly supporting the conclusion that full-length Nercc1 indeed has a higher affinity for Ran-GDP over Ran-GTP.

Figure 7
Nercc1 cellular localization. (a) Nercc1 immunolocalization in interphase. Specificity of the anti-Nercc1 C1 antibody. Cells were immunostained as described, using anti-Nercc1 C1 antibody (left panels) or the C1 antibody preincubated with the immunizing ...

The effect of Ran on Nercc1 activation in vitro was examined by preincubation of Nercc1 with Mg2+ and GST or GST-Ran, GST-Ran (GDPβs), or GST Ran (GMPPNP), and subsequent addition of 100 μM ATP. No significant differences were observed in rate of activation or in the final activity (data not shown).

Nercc1 is phosphorylated and activated during mitosis and can be phosphorylated in vitro by p34Cdc2

We next examined Nercc1 protein levels and activity during cell cycle progression. The level of Nercc1 protein in HeLa cell extracts remains constant during different phases of the cell cycle (G1/S, G2, M, G1); however, the Nercc1 polypeptide displays a marked slowing in electrophoretic mobility during mitosis (Fig. (Fig.6a),6a), which can be mimicked by treatment in vivo with the protein phosphatase inhibitor calyculin (data not shown). A similar electrophoretic slowing of Nercc1 occurs in CHO-K1, COS7, U2OS, or HEK293 cells arrested in mitosis (data not shown). In addition to nocodazole-induced mitotic arrest, we also examined mitotic cells prepared by shake-off from a culture that had been pseudosynchronized in G1/S by thymidine block and then released into the cell cycle (Fig. (Fig.6b).6b). Nercc1 is unmistakably up-shifted in the mitotic cells, whether normally cycling or nocodazole-arrested, establishing that the Nercc1 modification is a characteristic of cells progressing normally through mitosis, rather than the result of activation of the spindle checkpoint. In further experiments we used mitotic no codazole-arrested cells as a model of normal mitotic cells.

Figure 6
Nercc1 kinase is activated during mitosis and can be phosphorylated in vitro by p34Cdc2. (a) HeLa cells were isolated in different phases of the cell cycle. (G1/S) Cells arrested with aphidicolin (2 μg/mL overnight); (G2/M) cells arrested with ...

Endogenous Nercc1 kinase activity was assayed in immunoprecipitates prepared from HeLa cells, comparing cells growing exponentially to cells treated with nocodazole; the latter were divided into those detached after mitotic shake-off (mitotic cells) versus those that remain attached (non-mitotic cells). The Nercc1 kinase activity in mitotic cells is fourfold to fivefold higher than in exponentially growing cells, despite comparable polypeptide levels; nocodazole-arrested, non-mitotic cells show a small increase in Nercc1 kinase activity, probably caused by contaminating mitotic cells (Fig. (Fig.6c).6c). Similar results were obtained with U2OS cells (data not shown). Thus, Nercc1 is activated during mitosis.

To determine whether the observed mitotic Nercc1 activation and change in electrophoretical mobility were caused by phosphorylation, we incubated Nercc1 immunopurified from mitotic cells with phosphatase. As a control, recombinant Flag–Nercc1 preactivated by incubation with 100 μM ATP was also treated with phosphatase (Fig. (Fig.6d).6d). Phosphatase treatment increases Flag–Nercc1 electrophoretical mobility, and simultaneously reduces Nercc1 protein kinase activity against exogenous substrates, showing that Nercc1 activity depends on phosphorylation. When endogenous mitotic Nercc1 was incubated with phosphatase, a similar decrease in protein kinase activity was observed. Thus, Nercc1 activation in vitro and in vivo during mitosis is caused by phosphorylation.

Transiently expressed, catalytically inactive forms of recombinant Nercc1 (K81M or 338–979) show an up-shift on SDS PAGE in response to nocodazole, much the same as wild-type Nercc1 (data not shown). Such inactive Nercc1 mutants cannot autophosphorylate, indicating that the mitotic modification of Nercc1 at least in part is owing to another protein kinase; an obvious candidate is p34Cdc2. Recombinant full-length Flag–Nercc1 (K81M) eluted from Flag-agarose beads is phosphorylated in vitro by purified Xenopus active p34Cdc2/cyclin B (maturation promoting factor, MPF; Fig. Fig.6e).6e). MPF-catalyzed Nercc1 phosphorylation induces an up-shift in Nercc1 similar to that observed in vivo in mitotic cells, and overall 32P incorporation into Nercc1 (K81M) rapidly approaches 1 mole PO4/mole protein (Fig. (Fig.6e).6e). Similar results are obtained with cyclin B immunoprecipitates from nocodazole-arrested mitotic HeLa cells, whereas cyclin B immunoprecipitates from non-mitotic cells do not catalyze Nercc1 phosphorylation (data not shown). Inhibition of the Nercc1-phosphorylating activity in the cyclin B immunoprecipitate from mitotic cells by the CDK inhibitor roscovitine confirms the identity of the kinase activity as Cdc2. Thus, Nercc1 is an in vitro substrate for p34Cdc2, and this phosphorylation produces a change in Nercc1 electrophoretic mobility similar to that observed in mitotic cells, indicating that p34Cdc2 contributes to Nercc1 phosphorylation during mitosis.

It is important to point out that phosphorylation of Nercc1 by Cdc2/MPF in vitro does not significantly alter maximal Nercc1 kinase activity toward histone H3. Similarly, the up-shift in Nercc1 mobility that occurs on treatment of cells with calyculin is not accompanied by an increase in Nercc1 kinase activity (data not shown). Thus, although the autophosphorylation/autoactivation of Nercc1 in vitro is also accompanied by a slowing in electrophoretic mobility, the occurrence of an up-shift is not synonymous with Nercc1 activation. The functional consequences of Cdc2-catalyzed phosphorylation of Nercc1 during mitosis are not yet known.

Nercc1 cellular localization

Immunofluorescence studies using the N1 or C1 anti-Nercc1 peptide antibodies showed Nercc1 to have a finely granular cytoplasmic fluorescence in all cell lines tested (HeLa, PtK2, HEK293, NIH3T3). Nercc1 appears distributed diffusely in the cytoplasm without association with organelles, plasma membrane, or cytoskeletal elements (Fig. (Fig.7a;7a; see also Supplemental Fig. 3). We also performed nonequilibrium sucrose density gradient fractionation of HEK293 cells; Nercc1 sedimentation corresponded to that of other cytoplasmatic proteins (e.g., lactate dehydrogenase), and was distinct from a variety of membrane markers, for example, βCOP, a TGN marker. Overlay of Nercc1-enriched fractions with lighter sucrose followed by centrifugation to equilibrium did not result in Nercc1 translocation up into the low-density fraction, as occurs with membrane-bound proteins (data not shown). Thus Nercc1 is localized in the cytoplasm unattached to cellular membranes.

Notably, Nercc1 immunoreactivity is absent from the nucleus (Fig. (Fig.7a).7a). The lack of nuclear Nercc1 was also evident on overexpression of recombinant Flag–Nercc1 (Fig. (Fig.7c;7c; Supplemental Fig. 3). This was surprising, as Nercc1 contains a classical nuclear localization signal (NLS) that is fully functional when appended to the Nercc1 N terminus or to another polypeptide (Fig. (Fig.7c).7c). Careful examination of immunofluorescence specimens of cells subjected to a variety of treatments including leptomycin B, an inhibitor of CRM-dependent nuclear export (Supplemental Fig. 3), failed to uncover instances of endogenous Nercc1 in nuclei.

We next examined Nercc1 localization in mitotic cells (Fig. (Fig.7b).7b). HeLa cells were blocked in mitosis with nocodazole, or enriched in mitotic cells by double thymidine block followed by release and mitotic shake-off; in both instances, Nercc1 immunofluorescence in mitotic cells was diffusely distributed throughout the cell and conspicuously absent from the chromosomes. To test whether Nercc1 is associated with the mitotic spindle, mitotic HeLa cells were fixed after treatment for 1 min with the nonionic detergent saponin. Eg5, a microtubule-binding motor, is readily visualized on spindle microtubules after this light saponin treatment, whereas endogenous Nercc1 immunofluorescence is completely removed from the cells under these conditions. Thus Nercc1 is not (tightly) associated with the spindle microtubules, and is diffusely distributed through the cell during mitosis.

A series of Flag–Nercc1 mutants was examined for their cellular distribution during transient expression in HeLa cells (Fig. (Fig.7c).7c). Four types of subcellular distribution were observed: cytoplasmic, nucleocytoplasmic, predominantly nuclear, and exclusively nuclear. Overexpressed wild-type Nercc1 is distributed in the cytoplasm like endogenous Nercc1; however, ∼5% of cells show slight nuclear immunofluorescence. The inactive Nercc1 ATP-site mutant (K81M) shows a substantial nuclear component, suggesting that the NLS might be inactivated by autophosphorylation. The Nercc1(1–391) variant, although potentially capable of being activated, is nevertheless exclusively nuclear; this establishes the functionality of the Nercc1 NLS, as does the exclusive nuclear localization of a wild-type Nercc1 to which a copy of its endogenous NLS is fused at its N terminus.

The conversion of Nercc1 to forms that achieve nuclear localization results in the frequent occurrence of micronuclei, multiple nuclei, and lobed nuclear morphologies. Such phenotypes have been associated in other circumstances with lagging chromosomes and chromosome nondisjunction in anaphase (Cimini et al. 2001). The frequency of these morphologies was highest in cells expressing Nercc1(1–391), that is, an active kinase domain with the nuclear localization; however, expression of the cytoplasmic kinase-inactive variant Nercc1(1–739), as well as the nuclear/cytoplasmic variants, Nercc1 (K81M) and Nercc1(1–308) have a similar, but less marked effect (Fig. (Fig.7c,7c, column 5).

Nercc1 regulates mitotic progression

The structural similarities between Nercc1 and NIMA, the activation of Nercc1 during mitosis, the ability of Nercc1 to bind Ran in vitro and in vivo and to induce abnormal nuclear morphology when targeted to the nucleus, together point to the likelihood that Nercc1 is a mitotic regulator. A preliminary indication was provided by the observation that transfection of a plasmid encoding an eGFP–Nercc1 (K81M) fusion protein appeared to interdict cell division. Thus, time-lapse recordings of transfected HeLa cells showed that, whereas 78% of 70 cells transfected with a plasmid encoding eGFP alone underwent division within the subsequent 36 h, only 4% of 52 HeLa cells transfected with eGFP–Nercc1 (K81M) underwent division, and 85% proceeded to cell death as compared with 18% of the eGFP-transfected cells. Interestingly, even wild-type Nercc1 was somewhat toxic—only 29% of 31 HeLa cells transfected with an eGFP–Nercc1 plasmid proceeded through mitosis. The impact of the nuclear-localized Nercc1(1–391) was even more marked; only 1 of 45 HeLa cells transfected with eGFP–Nercc1(1–391) underwent division, and 72% of these cells were dead after 36 h.

To test directly whether Nercc1 participates in the control of mitotic progression, we used live observation of PtK2 cells after microinjection of affinity-purified anti-Nercc1 (peptide) antibodies or purified preimmune IgG. When Ptk2 cells were injected with Nercc1 antibodies during interphase, mitosis was never subsequently observed, preventing any conclusion. Therefore, antibody microinjection of cells in prophase was undertaken; such cells were identified by the presence of chromosome condensation and nucleolar disassembly. All such cells microinjected with normal rabbit IgG (5 at 2.5 mg/mL and 15 at 10 mg/mL) completed mitosis normally and produced daughter cells, save one, which had a lagging chromosome; this occurrence is consistent with the frequency of lagging chromosomes reported earlier for PtK cells (Izzo et al. 1998). In contrast, 14 cells of 30 cells (i.e., roughly 45%) microinjected with affinity-purified anti-Nercc1 (C1) IgG (2.5 mg/mL) showed mitotic abnormalities of two basic types. The first type involved abnormalities in chromosomal segregation associated with abnormal spindle dynamics. Thus, four cells never entered anaphase B (i.e., movement of poles with attached chromosomes in opposite directions), although the spindle was apparently normal; nevertheless, cytokinesis proceeded. In two experiments this resulted in the subsequent trapping of one or more chromosomes in the cytokinetic furrow, creating DNA bridges between the nuclei of daughter cells (Fig. (Fig.8a,8a, left column, A). In two other cases, separation of the chromosomes to opposite poles stopped prematurely, chromosome decondensation was observed, and a cytokinetic furrow formed to one side of the spindle, resulting in formation of one daughter cell with 4N DNA and one daughter cell without DNA (Fig. (Fig.8a,8a, middle column, B). The second type of abnormality concerned the formation of the mitotic spindle. In eight cells, the spindle was not visible on phase contrast images throughout the whole duration of the recording, and ∼40 min after the nuclear envelope breakdown, the chromosomes concentrated in the center of the rounded-up PtK2 cell, with chromosome arms extending far into the cell periphery (Fig. (Fig.8a,8a, right column, C). When fixed immediately after the recording, these cells showed a highly disrupted spindle (Fig. (Fig.8b,8b, anti-Nercc1; cf. with a cell microinjected with control IgG, control); although two separated centrosomes were visible, the cells showed an interphase array of microtubules.

Figure 8
The effect of microinjection of anti-Nercc1 IgG into PtK2 and CF-PAC1 cells. (a) PtK2 cells were microinjected with affinity-purified anti-Nercc1 (C1) IgG (2.5 mg/mL; typically, the volume of microinjected material comprised ∼10% of cell ...

Two anti-Nercc1 C1-microinjected cells formed a bipolar mitotic spindle, but anaphase started prematurely, specifically at only 8 min after the last monooriented chromosome acquired biorientation (this is 1 min less than the minimum time recorded for PtK cells; Rieder et al. 1994). Thus, in these cells, anaphase started without congression of chromosomes to the metaphase plate, although cell division proceeded normally from then on (data not shown).

Similar kinds of mitotic abnormalities, including a failure to enter anaphase B, were observed in 4 of 8 cells microinjected with an anti-Nercc1 IgG raised against a peptide sequence from the Nercc1 catalytic domain (E2 antibody, amino acids 80–94). Microinjection of 10 Ptk2cells with affinity-purified anti-Nercc1 N1 (amino acids 3–18) IgG did not alter the normal progression of mitosis (data not shown).

We also microinjected the Nercc1 C terminus antibody into CF-PAC1 cells in prophase. CF-PAC1 cells are a human cell line that contains levels of Nercc1 comparable to HeLa and HEK293 cells (data not shown) and that has been used previously for microinjection studies of spindle dynamics (Mountain et al. 1999). Three out of five microinjected cells arrested in prometaphase for 3–10 h with several monooriented chromosomes close to the spindle poles (Fig. (Fig.8c,8c, arrows); all five control cells microinjected with normal rabbit IgG showed normal mitosis. Among five CF-PAC1 cells microinjected early in prometaphase with anti-Nercc1 antibody, only one showed a similar mitotic defect, whereas the other four proceeded through mitosis normally.

The occurrence of similar mitotic abnormalities in Ptk2 cells microinjected with two independently prepared anti-Nercc1 antibodies, raised against different Nercc1 peptides, and the absence of these phenotypes in response to nonimmune IgG, together with the occurrence of similar abnormalities in CF-PAC1 cells indicate strongly that interference with Nercc1 is the basis for these phenotypes. In summary, microinjection of anti-Nercc1 (C-terminal peptide) C1 IgG and anti-Nercc1 (catalytic domain peptide) E2 IgG results in the frequent occurrence of abnormal spindle dynamics and abnormal chromosomal congression and segregation, indicating that Nercc1 ordinarily participates in the regulation of these processes.


Nercc1 kinase is a novel mitotic regulator

The Nercc1 kinase is a new member of the mammalian branch of the NIMA-like kinases. Perhaps the most consequential aspect of this work is the clear-cut demonstration that Nercc1, like NIMA, is a pleiotropic regulator of mitotic progression, participating in the control of spindle dynamics and chromosome separation. Among the previously characterized mammalian kinases with NIMA-like catalytic domains, only Nek2 has been shown to be clearly involved in any aspect of mitotic regulation, that is, centrosome separation. Although mammalian cells were shown to respond to NIMA overexpression with chromatin condensation and are blocked in G2 by different nonfunctional versions of NIMA, it has not previously been clear whether functional homologs of NIMA exist in metazoans (O'Connell et al. 1994; Lu and Hunter 1995). None of the described mammalian enzymes with protein kinase domains homologous to NIMA (Nek1–7; Nigg 2001) appears to have functions similar to that of Aspergillus NIMA, that is, control of the G2/M transition (Osmani et al. 1991a; Lu and Means 1994), chromosome condensation (Osmani et al. 1988b; O'Connell et al. 1994), and spindle and nuclear envelope organization during and after mitosis (Osmani et al. 1991b).

We show that microinjection of interfering anti-Nercc1 IgGs into PtK2 and CF-PAC1 cells in prophase induces several types of abnormalities. Many Ptk2 cells microinjected with anti-Nercc1 antibody arrest in prometaphase without an observable spindle. Other cells show a bipolar spindle, but defective chromosome orientation and segregation result in aneuploidy after cytokinesis. In a few cells, spindle separation is markedly defective, but cytokinesis proceeds, resulting in the sequestration of the entire spindle and 4N DNA content into only one of the daughter cells. CF-PAC1 cells microinjected in prophase with anti-Nercc1 antibody also show abnormalities in chromosome attachment, but in contrast to Ptk2 cells, CF-PAC1 cells microinjected with anti-Nercc1 antibody in prophase arrest in prometaphase with monooriented chromosomes.

Inasmuch as these IgG injections were made after chromosome condensation, we have no direct evidence concerning the participation of Nercc1 in this or other earlier steps in G2/M progression. Nevertheless, overexpression of nuclear forms of Nercc1, especially Nercc1(1–391) and Nercc1(1–308), produce markedly abnormal morphologies of the interphase nucleus (Fig. (Fig.7c),7c), and these Nercc1 variants collect at peripheral sites near the tips of lobed nuclei. The basis for this appearance is unknown, and its relationship to NIMA-induced chromosomal condensation in mammalian cells will probably require a side-by-side comparison.

The molecular basis for the abnormalities observed when anti-Nercc1 IgG is introduced into mitotic cells is not known. The phenotypes suggest possible roles for Nercc1 in spindle assembly and dynamics as well as in chromosome attachment, alignment at the spindle midzone, and segregation. The occurrence of arrest in prometaphase suggests activation of the spindle checkpoint, whereas the instances in which mitotic progression of antibody-microinjected Ptk2 cells continues through anaphase and cytokinesis despite chromosome misalignment and maldistribution indicate that the metaphase–anaphase and mitotic exit checkpoints have been bypassed. A possible explanation is that Nercc1 regulates one or more components of the cell cycle machinery involved in both spindle formation and checkpoint action. Motor proteins have this characteristic and are thus good candidates to be targets for Nercc1 (Brunet and Vernos 2001).

In addition to possible functional homology, Nercc1 has a striking number of structural similarities with NIMA aside from their homologous catalytic domains. Nercc1 has a C-terminal tail containing an NLS, a substantial set of S/TP sites, several PEST regions, and a coiled coil that serves as a homooligomerization motif. In addition, Nercc1 is an in vitro substrate of p34Cdc2 and shows increased activity during mitosis. Nevertheless, Nercc1 also displays some remarkable differences from NIMA, the most conspicuous being the presence of a domain homologous to RCC1 and the ability to bind Ran. Also, whereas NIMA is localized to the nucleus and its levels change greatly during cell cycle progression, Nercc1 is cytoplasmic in interphase and its protein levels do not appear to change during the cell cycle. Thus, it is highly unlikely that Nercc1 is an exact mammalian equivalent of NIMA. More likely, the numerous functions of NIMA characterized in Aspergillus have been parsed out among a number of kinases in mammalian cells, which differ in regulation and perhaps specificity; Nercc1 certainly appears to be one of these.

In this regard, the association of Nercc1 with Nek6 and Nek7 (data not shown) requires comment. The tight association of Nercc1 with these two kinases suggests that they represent elements in a signal transduction cascade or a linked effector unit or possibly both. Apart from the role of Nek6/7 as a candidate p70 S6 kinase-kinase (Belham et al. 2001), the cellular responses to Nek6/7 are as yet uncharacterized. When extracted after transient expression in normally cycling cells, Nek 6/7 shows considerable basal activity, in contrast to Nercc1. We showed previously that the spontaneous activity of recombinant Nek6 is reversed by protein phosphatase treatment in vitro. Preliminary experiments indicate that Nercc1 is capable of phosphorylating and activating Nek7 in vitro. It is therefore conceivable that some or all of the phenotypes observed on microinjection of interfering anti Nercc1 IgG are caused by interference with Nek6/7 function.

Regulation of Nercc1 kinase function

Our analysis thus far of the regulation of Nercc1 activity indicates that in vitro, the recombinant Nercc1 polypeptide is a homooligomer that is maintained in an inactive state by occlusion of its catalytic domain by the succeeding RCC1-like domain; this inhibition may occur either in cis or in trans within the dimer. The monomeric variant Nercc1(1–739) also has low activity and is almost entirely resistant to autoactivation in vitro by Mg2+ plus ATP. The further deletion of the RCC1-like domain produces Nercc1(1–391); this variant also shows low basal activity but is capable of significantly greater autoactivation in the presence of Mg2+-ATP than is Nercc1(1–739), although at rates far below wild type. In contrast, a deletion of the RCC1-like domain that leaves the Nercc1 dimer intact, that is, Nercc1(Δ347–732), shows very high basal activity, either through spontaneous activation in vivo, or essentially instantaneous autoactivation in vitro upon addition of Mg2+-ATP. The very strong dependence on oligomerization and Mg2+-ATP for activation in vitro points to intramolecular trans-phosphorylation of the Nercc1 activation loop as the likely basis for activation in vivo.

In view of the spontaneous autoactivation of Nercc1 in vitro in the presence of Mg2+-ATP, the finding that both endogenous and recombinant Nercc1 are extracted from cycling cells in a low activity state indicates that one or more powerful exogenous negative regulatory inputs act on Nercc1 during interphase. In addition, the substantial increase in the specific activity of endogenous Nercc1 seen in mitosis suggests the occurrence of a mitosis-specific loss of one or more of these inhibitory influences. One obvious set of candidates for such an inhibitor is the cytoplasmic Ser/Thr phosphatases, which may simply reverse Nercc1 autophosphorylation. Nevertheless, calyculin A treatment of cells, although causing Nercc1 hyperphosphorylation, as reflected by a slowing in electrophoretic mobility, does not result in the activation of Nercc1 kinase activity. Consequently, we infer that Nercc1 autophosphorylation must be maintained at a very low level during interphase. The rigidly cytoplasmic localization of Nercc1 during interphase may be important not only to prevent inappropriate access of Nercc1 to nuclear targets, but also for maintaining Nercc1 in an inhibited state, probably through the binding of Nercc1 to a cytoplasmic inhibitor. Nevertheless, simply targeting Nercc1 to the nucleus, for example, by fusing an NLS to the Nercc1 N terminus, does not result in Nercc1 activation. Thus we infer that the disinhibition/activation of Nercc1 depends on the availability of elements that appear as cells progress from G2 into M. We have thus far identified two elements that interact with Nercc1, and whose availability is known to change with this phase of the cell cycle, namely, cyclin B/Cdc2, which can phosphorylate Nercc1 to a considerable extent in vitro, and the small GTPase Ran. Phosphorylation of Nercc1 by MPF does not alter the maximal Nercc1 activity attainable after autophosphorylation, and in preliminary experiments does not appear to alter the rate of Nercc1 autoactivation in vitro, although the latter conclusion is as yet tentative given the technical difficulties of those experiments. In addition, we have not yet determined whether MPF-catalyzed Nercc1 phosphorylation alters Nercc1 binding to its known interactors, Ran and Nek6/7.

As to the interactions of Ran with Nercc1, our in vitro assays do not as yet show any major impact of Ran on the rate of Nercc1 autoactivation. Nevertheless, we are intrigued by the specific and relatively tight binding of Ran to the Nercc1 catalytic domain in vitro and in vivo, as well as the important role of the Nercc1 RCC1-like domain as a negative regulatory element. The Nercc1 RCC1-like domain also binds Ran specifically, although less tightly than the Nercc1 catalytic domain.

Although other proteins have been described with domains similar to RCC1 (e.g., Herc 1–3; Rosa et al. 1996; Guo et al. 1998; Ji et al. 1999), that of Nercc1 is, to our knowledge, the first example of an RCC1-like domain (other than the RCC1 itself) shown to bind Ran. We have not yet determined whether the Nercc1 RCC1-like domain has any GEF activity toward Ran, although based on sequence comparison we think this highly improbable (see Fig. Fig.1c).1c). Moreover, a Ran GEF with a diffuse cytoplasmic distribution would certainly disrupt the RanGDP/RanGTP gradient that drives the nucleocytoplasmatic transport in interphase.

As to the possible role of Ran in the regulation of Nercc1, we offer the following speculations. Given the exclusive cytoplasmic localization of Ran-GDP in interphase and its very high concentration (∼1% of HeLa cell protein), as well as the preferential binding of Nercc1 to Ran-GDP (Fig. (Fig.5d),5d), we propose that Ran-GDP, acting together with one or more as yet unidentified elements, plays a role in maintaining the inhibited state of Nercc1 in interphase cells. During mitosis, with dissolution of the nuclear membrane, Ran assumes new functions. Recent work has established that in mitosis, as in interphase, the capacity of the RCC1–GEF/Ran system to serve as a positional marker continues to be used, through the focal generation of Ran-GTP in the vicinity of the chromosome-bound GEF; this generation of Ran-GTP is critical in directing the construction of the mitotic spindle as well as in the reassembly of the nuclear envelope after telophase (Azuma et al. 1999; Hetzer et al. 2000). The gradient of Ran-GTP formed around the chromosomes by the action of RCC1 (Kalab et al. 2002) controls microtubule polymerization and motor activity and thus promotes aster formation and spindle assembly around chromosomes (for reviews, see Kahana and Cleveland 1999; Heald and Weis 2000). The mechanism through which Ran controls microtubule polymerization is similar to that of nucleocytoplasmic transport: binding of Ran-GTP to importins frees and activates different aster-promoting activities that are inactivated by importin binding (for reviews, see Dasso 2001; Walczak 2001). How Ran controls other steps involved in aster formation and spindle assembly (e.g., the activity of motor proteins like Eg5) and nuclear envelope formation, or whether Ran controls other aspects of mitosis is presently unknown (for a review on Ran and cell cycle control, see Moore 2001). Based on the phenotypes elicited by microinjection of anti-Nercc1 IgG into mitotic cells, and the ability of Nercc1 to bind Ran, we propose that the activation of Nercc1 during mitosis (which is ultimately caused by the intramolecular transphosphorylation of the Nercc1 activation loop) and/or the execution of its cellular functions will prove to involve the displacement of Ran-GDP in the vicinity of the chromosomes; this implies that although diffusely distributed, Nercc1 is activated and/or acts primarily in the vicinity of the chromosomes. Certainly the control of protein kinase localization and activation by small GTPases, as first shown for Ras and Raf, is now recognized as a general regulatory mechanism in the regulation of protein kinase function. Reconstituting in vitro the apparatus underlying the cell cycle-dependent regulation of Nercc1 activity will be a substantial challenge.

In conclusion, Nercc1 is a mammalian NIMA-like kinase that acts as a regulator of spindle function and chromosome segregation. Nercc1 is tightly bound to another NIMA-like protein kinase, Nek6/7; the contribution of each kinase to the function of the other is as yet unknown. Nercc1 is activated in mitosis by disinhibition and intramolecular autophosphorylation. It is a target for cyclinB/Cdc2 and binds specifically to the Ran GTPase through its catalytic and novel RCC1-like domain. The significance of Cdc2 phosphorylation and Ran binding in Nercc1 activation, targeting, and function, as well as the immediate cellular substrates of Nercc1 await discovery.

Materials and methods

Protein sequencing, cDNA cloning and manipulation

The cloning of the Nercc1 cDNA and the construction of the different DNA plasmids used in this work is described in the Supplemental Material (available online at http://www.genesdev.org).

Cell culture and transfection

See Supplemental Material (available online at http://www.genesdev.org).

Cell lysis, immunoprecipitation, in vitro binding, and immunoblotting

Cells were rinsed with PBS, flash-frozen in liquid nitrogen, and stored at −70°C. Cell lysis used a buffer containing: 50 mM Tris (pH 7.1), 100 mM NaCl, 1 mM DTT, 1 mM EDTA, 1 mM EGTA, 10 mM β-glycerophosphate, 2 mM Na3VO4, 25 nM calyculin A, 1% TX100, plus protease inhibitors (EDTA-free tablets; Roche). Protein concentration was determined by the Bradford reagent (BioRad). Immunoprecipitations were carried out with the indicated antibodies prebound to protein A/G-agarose (Santa Cruz), and washed in the lysis buffer containing 0.5 M LiCl.

Experiments involving Ran used a different (Ran) lysis buffer: 50 mM HEPES (pH 7.4), 0.1 M NaCl, 1 mM DTT, 5 mM MgCl2, 2 mM Na3VO4, 25 nM calyculin A, 1% Triton X-100, plus protease inhibitors (EDTA-free tablets; Roche); IPs were washed with the same buffer. The binding of Ran to Nercc1 in vitro was carried out in Ran binding buffer (20 mM MOPS at pH 7.4, 0.1 M potassium acetate, 5 mM magnesium acetate, 2 mM DTT, 0.5% BSA, 0.05% Tween-20); washes were carried out in the same buffer. Immunoblotting was carried out after separation of proteins by SDS-PAGE and transfer to PVDF membranes; blots were probed with the antibodies indicated, and bound antibodies were detected by ECL chemiluminescence (Amersham).

Gel filtration

The 293 cells were lysed in 1% TX-100 lysis buffer, ultracentrifuged at 100,000g for 40 min, and loaded to a precalibrated HiPrep 16/60 Sephacryl S-300 High Resolution column (Pharmacia). Gel filtration was carried out in 50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM DTT buffer at 0.5 mL/min.

Protein kinase assays

Protein kinase assays were carried out after immunoprecipitation; recombinant Nercc1 was isolated using anti-Flag antibodies prebound to protein A/G-agarose beads. Endogenous Nercc1 was immunopurified using N1 antibodies prebound to protein A/G-agarose beads. Complexes were washed sequentially with lysis buffer and phosphorylation buffer (50 mM MOPS at pH 7.4, 1 mM DTT, 1 mM EGTA, 5 mM MgCl2, 10 mM β-glycerophosphate, 25 nM calyculin A). Nercc1 autoactivation was carried out by incubation of immobilized Nercc1 in phosphorylation buffer plus 100 μM ATP at 25°C for the indicated times. Activation was terminated by washing the immobilized Nercc1 in phosphorylation buffer, and the protein activity achieved was assayed by incubation at 30°C in phosphorylation buffer supplemented with either 10 μM or 100 μM [γ-32P]ATP, with an exogenous substrate, usually histone H3, as indicated. Assays were stopped by addition of electrophoresis sample buffer and boiling, and the proteins were resolved by SDS-PAGE. 32P incorporation was measured with a PhosphorImager system or by liquid scintillation counting, as indicated.


Cells grown on coverslips were rinsed with PBS, fixed in methanol at −20°C for 15 min, rinsed twice with PBS, and incubated for 30 min at room temperature with the appropriate dilution of primary antibody in PBS. To visualize endogenous Nercc1, affinity-purified anti-Nercc1 peptide antibodies (N1 and C1) were used at 10 μg/mL. Microtubules were visualized with an α/β-tubulin-specific antibody. Coverslips were washed with PBS, and incubated with labeled secondary antibodies from corresponding species in appropriate combination: fluorescein or rhodamine X-conjugated donkey anti-rabbit, Cy2 or rhodamine X–conjugated donkey anti-mouse (each at 1:450). Incubation was terminated with a rinse in PBS, and the coverslips were mounted on a microscope slide. For immunodetection blocking, Nercc1 C1 or N1 antibody was incubated at 37°C for 30 min with a 15-fold molar excess of immunizing peptide. After centrifugation at 12,000g for 10 min, the mixture was used for immunoblotting or immunocytochemistry, as indicated.

Microinjections and time-lapse recordings

For real-time observation of the effects of recombinant Nercc1 expression, both wild-type and variant, on cellular morphology and behavior during one cell cycle, HeLa cells grown on 25-mm glass coverslips were transfected with pEGFP-C2 vector or this vector encoding GFP fusions with Nercc1 wild-type, Nercc1 (K81M), or Nercc1(1–391) using Fugene (Roche Molecular Biochemicals). Fugene-containing medium was removed after 12 h, and DMEM supplemented with 10% calf serum and penicillin–streptomycin was added after rinsing. The percentage of transfected cells undergoing division within 24 h was monitored. Using this transfection procedure, cells transfected with empty pEGFP-C2 underwent division at a frequency similar to nontransfected cells. The coverslips (in a Sykes-Moore chamber) were mounted on a microscope stage prewarmed to 37°C; a region with the highest density of transfected cells (GFP-positive) was selected for observation, and phase contrast images were acquired using a 40× 1.0 NA objective every 10 min for 25 h. Light was kept to a minimum during image acquisitions and shuttered between acquisitions.

To observe the effect of anti-Nercc1 antibodies on mitosis, PtK2 cells were grown to subconfluency on 25-mm round glass coverslips placed inside 35-mm cell culture dishes. A cell in prophase was found using phase contrast optics and microinjected in the period between the nucleolar disassembly and nuclear envelope breakdown with either 2.5 or 10 μg/μL normal rabbit IgG (Jackson Immunoresearch) for control experiments, or with 2.5 mg/mL rabbit anti-Nercc1 C- or N-terminus or kinase domain antibody with 0.5 μg/μL rhodamine-labeled dextran 3000 (Molecular Probes). Typically, the volume of microinjected material comprised ∼10% of cell volume. Immediately after microinjection, the coverslip with microinjected cells was placed in a Sykes-Moore chamber (Bellco Glass) filled with bicarbonate-free DMEM supplemented with 10% fetal Calf Serum. The chamber was transferred onto the stage of a Zeiss Axiovert 100M microscope maintained at 37°C with the aid of an Air-Therm heater controller (World Precision Instruments) and a custom-made microscope incubator. Microinjected cells were found by rhodamine fluorescence using a maximum possible density neutral density filter (typically, ND 1.0; Chroma Technology). Phase contrast images were acquired every 20 or 30 sec with a Hamamatsu Orca-100 CCD camera driven by Metamorph 4.0 (Universal Imaging Corporation); we used a 100× 1.4 NA objective and light was kept to a minimum during image acquisitions and shuttered between acquisitions.


We thank Y. Yin for Northern blots, Y. Lin for the mouse tissue protein membranes, E. Casacuberta for help with ORF prediction, and J. Prendable for help with the manuscript. We are grateful to A. Khodjakov and C. Rieder for help interpreting the anti-Nercc1 microinjection experiments. We are also grateful to I. Macara for the different Ran variant cDNAs and RCC1 cDNA, and to J. Maller for purified MPF. This work was supported in part by DK17776.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 USC section 1734 solely to indicate this fact.


E-MAIL ude.dravrah.hgm.xileh@hcurva; FAX (617) 726-5649.

Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.972202.


  • Azuma Y, Renault L, Garcia-Ranea JA, Valencia A, Nishimoto T, Wittinghofer A. Model of the ran–RCC1 interaction using biochemical and docking experiments. J Mol Biol. 1999;289:1119–1130. [PubMed]
  • Belham C, Comb MJ, Avruch J. Identification of the NIMA family kinases NEK6/7 as regulators of the p70 ribosomal S6 kinase. Curr Biol. 2001;11:1155–1167. [PubMed]
  • Bischoff JR, Plowman GD. The Aurora/Ipl1p kinase family: Regulators of chromosome segregation and cytokinesis. Trends Cell Biol. 1999;9:454–459. [PubMed]
  • Borodovsky M, McIninch J. GeneMark: Parallel gene recognition for both DNA strands. Comput Chem. 1993;17:123–133.
  • Brunet S, Vernos I. Chromosome motors on the move: From motion to spindle checkpoint activity. EMBO Rep. 2001;2:669–673. [PMC free article] [PubMed]
  • Burge C, Karlin S. Prediction of complete gene structures in human genomic DNA. J Mol Biol. 1997;268:78–94. [PubMed]
  • Cimini D, Howell B, Maddox P, Khodjakov A, Degrassi F, Salmon ED. Merotelic kinetochore orientation is a major mechanism of aneuploidy in mitotic mammalian tissue cells. J Cell Biol. 2001;153:517–527. [PMC free article] [PubMed]
  • Dasso M. Running on Ran: Nuclear transport and the mitotic spindle. Cell. 2001;104:321–324. [PubMed]
  • Fry AM, Nigg EA. Cell cycle. The NIMA kinase joins forces with Cdc2. Curr Biol. 1995;5:1122–1125. [PubMed]
  • ————— Characterization of mammalian NIMA-related kinases. Methods Enzymol. 1997;283:270–282. [PubMed]
  • Glover DM, Hagan IM, Tavares AA. Polo-like kinases: A team that plays throughout mitosis. Genes & Dev. 1998;12:3777–3787. [PubMed]
  • Guo Q, Xie J, Dang CV, Liu ET, Bishop JM. Identification of a large Myc-binding protein that contains RCC1-like repeats. Proc Natl Acad Sci. 1998;95:9172–9177. [PMC free article] [PubMed]
  • Heald R, Weis K. Spindles get the ran around. Trends Cell Biol. 2000;10:1–4. [PubMed]
  • Hetzer M, Bilbao-Cortes D, Walther TC, Gruss OJ, Mattaj IW. GTP hydrolysis by Ran is required for nuclear envelope assembly. Mol Cell. 2000;5:1013–1024. [PubMed]
  • Holland PM, Milne A, Garka K, Johnson RS, Willis C, Sims JE, Rauch CT, Bird TA, Virca GD. Purification, cloning, and characterization of Nek8, a novel NIMA-related kinase, and its candidate substrate Bicd2. J Biol Chem. 2002;277:16229–16240. [PubMed]
  • Izzo M, Antoccia A, Degrassi F, Tanzarella C. Immunofluorescence analysis of diazepam-induced mitotic apparatus anomalies and chromosome loss in Chinese hamster cells. Mutagenesis. 1998;13:445–451. [PubMed]
  • Ji Y, Walkowicz MJ, Buiting K, Johnson DK, Tarvin RE, Rinchik EM, Horsthemke B, Stubbs L, Nicholls RD. The ancestral gene for transcribed, low-copy repeats in the Prader–Willi/Angelman region encodes a large protein implicated in protein trafficking, which is deficient in mice with neuromuscular and spermiogenic abnormalities. Hum Mol Genet. 1999;8:533–542. [PubMed]
  • Kahana JA, Cleveland DW. Beyond nuclear transport. Ran-GTP as a determinant of spindle assembly. J Cell Biol. 1999;146:1205–1210. [PMC free article] [PubMed]
  • Kalab P, Weis K, Heald R. Visualization of a Ran-GTP gradient in interphase and mitotic Xenopus egg extracts. Science. 2002;295:2452–2456. [PubMed]
  • Kandli M, Feige E, Chen A, Kilfin G, Motro B. Isolation and characterization of two evolutionarily conserved murine kinases (Nek6 and Nek7) related to the fungal mitotic regulator, NIMA. Genomics. 2000;68:187–196. [PubMed]
  • Lies CM, Cheng J, James SW, Morris NR, O'Connell MJ, Mirabito PM. BIMAAPC3, a component of the Aspergillus anaphase promoting complex/cyclosome, is required for a G2 checkpoint blocking entry into mitosis in the absence of NIMA function. J Cell Sci. 1998;111:1453–1465. [PubMed]
  • Lu KP, Hunter T. Evidence for a NIMA-like mitotic pathway in vertebrate cells. Cell. 1995;81:413–424. [PubMed]
  • Lu KP, Means AR. Expression of the noncatalytic domain of the NIMA kinase causes a G2 arrest in Aspergillus nidulans. EMBO J. 1994;13:2103–2113. [PMC free article] [PubMed]
  • Mayor T, Meraldi P, Stierhof YD, Nigg EA, Fry AM. Protein kinases in control of the centrosome cycle. FEBS Lett. 1999;452:92–95. [PubMed]
  • Moore JD. The Ran-GTPase and cell-cycle control. Bioessays. 2001;23:77–85. [PubMed]
  • Mountain V, Simerly C, Howard L, Ando A, Schatten G, Compton DA. The kinesin-related protein, HSET, opposes the activity of Eg5 and cross-links microtubules in the mammalian mitotic spindle. J Cell Biol. 1999;147:351–365. [PMC free article] [PubMed]
  • Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev. 2001;2:21–32. [PubMed]
  • O'Connell MJ, Osmani AH, Morris NR, Osmani SA. An extra copy of nimEcyclinB elevates pre-MPF levels and partially suppresses mutation of nimTcdc25 in Aspergillus nidulans. EMBO J. 1992;11:2139–2149. [PMC free article] [PubMed]
  • O'Connell MJ, Norbury C, Nurse P. Premature chromatin condensation upon accumulation of NIMA. EMBO J. 1994;13:4926–4937. [PMC free article] [PubMed]
  • Osmani SA, Ye XS. Cell cycle regulation in Aspergillus by two protein kinases. Biochem J. 1996;317:633–641. [PMC free article] [PubMed]
  • Osmani SA, Pu RT, Morris NR. Mitotic induction and maintenance by overexpression of a G2-specific gene that encodes a potential protein kinase. Cell. 1988a;53:237–244. [PubMed]
  • Osmani SA, Engle DB, Doonan JH, Morris NR. Spindle formation and chromatin condensation in cells blocked at interphase by mutation of a negative cell cycle control gene. Cell. 1988b;52:241–251. [PubMed]
  • Osmani AH, McGuire SL, Osmani SA. Parallel activation of the NIMA and p34cdc2 cell cycle-regulated protein kinases is required to initiate mitosis in A. nidulans. Cell. 1991a;67:283–291. [PubMed]
  • Osmani AH, O'Donnell K, Pu RT, Osmani SA. Activation of the nimA protein kinase plays a unique role during mitosis that cannot be bypassed by absence of the bimE checkpoint. EMBO J. 1991b;10:2669–2679. [PMC free article] [PubMed]
  • Pu RT, Osmani SA. Mitotic destruction of the cell cycle regulated NIMA protein kinase of Aspergillus nidulans is required for mitotic exit. EMBO J. 1995;14:995–1003. [PMC free article] [PubMed]
  • Pu RT, Xu G, Wu L, Vierula J, O'Donnell K, Ye XS, Osmani SA. Isolation of a functional homolog of the cell cycle-specific NIMA protein kinase of Aspergillus nidulans and functional analysis of conserved residues. J Biol Chem. 1995;270:18110–18116. [PubMed]
  • Renault L, Nassar N, Vetter I, Becker J, Klebe C, Roth M, Wittinghofer A. The 1.7 A crystal structure of the regulator of chromosome condensation (RCC1) reveals a seven-bladed propeller. Nature. 1998;392:97–101. [PubMed]
  • Rieder CL, Schultz A, Cole R, Sluder G. Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attachment to the spindle. J Cell Biol. 1994;127:1301–1310. [PMC free article] [PubMed]
  • Rosa JL, Casaroli-Marano RP, Buckler AJ, Vilaro S, Barbacid M. p619, a giant protein related to the chromosome condensation regulator RCC1, stimulates guanine nucleotide exchange on ARF1 and Rab proteins. EMBO J. 1996;15:4262–4273. [PMC free article] [PubMed]
  • Walczak CE. Ran hits the ground running. Nat Cell Biol. 2001;3:E69–E70. [PubMed]
  • Wu L, Osmani SA, Mirabito PM. A role for NIMA in the nuclear localization of cyclin B in Aspergillus nidulans. J Cell Biol. 1998;141:1575–1587. [PMC free article] [PubMed]
  • Ye XS, Xu G, Pu RT, Fincher RR, McGuire SL, Osmani AH, Osmani SA. The NIMA protein kinase is hyperphosphorylated and activated downstream of p34cdc2/cyclin B: Coordination of two mitosis promoting kinases. EMBO J. 1995;14:986–994. [PMC free article] [PubMed]

Articles from Genes & Development are provided here courtesy of Cold Spring Harbor Laboratory Press
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Conserved Domains
    Conserved Domains
    Conserved Domain Database (CDD) records that cite the current articles. Citations are from the CDD source database records (PFAM, SMART).
  • Gene
    Gene records that cite the current articles. Citations in Gene are added manually by NCBI or imported from outside public resources.
  • Gene (nucleotide)
    Gene (nucleotide)
    Records in Gene identified from shared sequence and PMC links.
  • GEO Profiles
    GEO Profiles
    Gene Expression Omnibus (GEO) Profiles of molecular abundance data. The current articles are references on the Gene record associated with the GEO profile.
  • HomoloGene
    HomoloGene clusters of homologous genes and sequences that cite the current articles. These are references on the Gene and sequence records in the HomoloGene entry.
  • MedGen
    Related information in MedGen
  • Nucleotide
    Primary database (GenBank) nucleotide records reported in the current articles as well as Reference Sequences (RefSeqs) that include the articles as references.
  • OMIM
    Genome Survey Sequence (GSS) nucleotide records reported in the current articles.
  • Pathways + GO
    Pathways + GO
    Pathways and biological systems (BioSystems) that cite the current articles. Citations are from the BioSystems source databases (KEGG and BioCyc).
  • Protein
    Protein translation features of primary database (GenBank) nucleotide records reported in the current articles as well as Reference Sequences (RefSeqs) that include the articles as references.
  • PubMed
    PubMed citations for these articles
  • Taxonomy
    Taxonomy records associated with the current articles through taxonomic information on related molecular database records (Nucleotide, Protein, Gene, SNP, Structure).
  • Taxonomy Tree
    Taxonomy Tree

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...